Senores Pharmaceuticals IPO Details
| IPO Open Date: | December 20, 2024 |
| IPO Close Date: | December 24, 2024 |
| Face Value: | ₹10 Per Equity Share |
| IPO Price Band: | ₹[.] to ₹[.] Per Share |
| Issue Size: | Approx ₹[.] Crores |
| Fresh Issue: | Approx ₹500 Crores |
| Offer for Sale: | Approx 21,00,000 Equity Shares |
| Issue Type: | Book Built Issue |
| IPO Listing: | BSE & NSE |
| Retail Quota: | Not more than 10% |
| QIB Quota: | Not more than 75% |
| NII Quota: | Not more than 15% |
| DRHP Draft Prospectus: | Click Here |
| RHP Draft Prospectus: | Click Here |
| Anchor Investors List: | Click Here |
Senores Pharmaceuticals IPO Market Lot
The Senores Pharmaceuticals IPO minimum market lot is [.] shares with ₹[.] application amount. The retail investors can apply up-to 13 lots with [.] shares or ₹[.] amount.
| Application | Lot Size | Shares | Amount |
| Retail Minimum | 1 | – | ₹- |
| Retail Maximum | 13 | – | ₹- |
| S-HNI Minimum | 14 | – | ₹- |
| B-HNI Minimum | 68 | – | ₹- |
Senores Pharmaceuticals IPO Dates
The Senores Pharmaceuticals IPO date is December 20 and the close date is December 24. The Senores Pharmaceuticals IPO allotment will be finalized on December 26 and the IPO listing on December 30.
| IPO Open Date: | December 20, 2024 |
| IPO Close Date: | December 24, 2024 |
| Basis of Allotment: | December 26, 2024 |
| Refunds: | December 27, 2024 |
| Credit to Demat Account: | December 27, 2024 |
| IPO Listing Date: | December 30, 2024 |
Promoters of Senores Pharmaceuticals IPO
The promoters of the company are Swapnil Jatinbhai Shah and Ashokkumar Vijaysinh Barot
About Senores Pharmaceuticals IPO
To be updated soon
Senores Pharmaceuticals IPO Company Financial Report
The company reported revenue of ₹217.34 crores in 2024 against ₹39.02 crore in 2023. The company reported loss of ₹32.71 crores in 2024 against Profit of ₹8.43 crores in 2023.
Amount ₹ in Crores
| Period Ended | Revenue | Expense | Profit After Tax | Assets |
| 2022 | ₹14.63 | ₹13.49 | ₹0.99 | ₹59.15 |
| 2023 | ₹39.02 | ₹26.58 | ₹8.43 | ₹131.05 |
| 2024 | ₹217.34 | ₹192.40 | ₹32.71 | ₹621.88 |
Senores Pharmaceuticals IPO Valuation – FY2024
Check Senores Pharmaceuticals IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| KPI | Values |
| ROE: | 23.60% |
| ROCE: | 11.73% |
| EBITDA Margin: | 20.70% |
| PAT Margin: | 15.25% |
| Debt to equity ratio: | 1.07 |
| Earning Per Share (EPS): | ₹13.67 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 23.60% |
| Net Asset Value (NAV): | ₹66.96 |
Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Ajanta Pharma Limited | 64.82 | 34.37 | 23.47% | 281.60 | 4208.71 Cr. |
| Alembic Pharmaceuticals Limited | 31.33 | 34.58 | 13.40% | 245.12 | 6228.63 Cr. |
| Caplin Point Laboratories Limited | 60.79 | 25.23 | 21.69% | 309.03 | 1694.10 Cr. |
| Gland Pharma Limited | 46.90 | 43.73 | 9.26% | 529.65 | 5664.72 Cr. |
| Strides Pharma Science Limited | (7.76) | NA | (4.44%) | 225.43 | 4051.12 Cr. |
Objects of the Issue
- Funding the capital expenditure requirements by investment in of one of our Subsidiaries, Havix Group, Inc. d/b/a Aavis Pharmaceuticals (“Havix”), for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility;
- Re-payment/pre-payment, in full or in part, of certain borrowings availed by our Company and our Subsidiaries, namely, Havix, Ratnatris Pharmaceutical Private Limited (“Ratnatris”) and Senores Pharmaceuticals Inc. (“SPI”);
- Funding the working capital requirements of our Company and our Subsidiaries, namely, SPI and Ratnatris; and
- Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes.
Senores Pharmaceuticals IPO Review
- Canara Bank –
- DRChoksey FinServ –
- Emkay Global –
- Hem Securities –
- IDBI Capital –
- Marwadi Shares –
- Nirmal Bang –
- SBICAP Securities –
- Sharekhan –
- SMC Global –
- Sushil Finance –
- Swastika Investmart –
- Ventura Securities –
- Geojit –
- Reliance Securities –
- Capital Market –
- BP Wealth –
- ICICIdirect –
- Choice Broking –
Senores Pharmaceuticals IPO Registrar
Link Intime India Private Limited
Phone: +91 8108114949
E-mail: [email protected]
Website: https://linkintime.co.in/initial_offer/
IPO Lead Managers aka Merchant Bankers
- Equirus Capital Private Limited
- Ambit Private Limited
- Nuvama Wealth Management Limited
Company Address
Senores Pharmaceuticals Limited
1101 to 1103,
11th floor, South Tower, ONE 42
Opposite Jayantilal Park,
Ambali Bopal Road, Ahmedabad,
Ahmedabad, Gujarat,
India, 380054
Phone: +91 -79-29999857
Email: [email protected];
Website: www. senorespharma.com
Senores Pharmaceuticals IPO FAQs
What is Senores Pharmaceuticals IPO?
When Senores Pharmaceuticals IPO will open for subscription?
What is Senores Pharmaceuticals IPO Investors Portion?
How to Apply the Senores Pharmaceuticals IPO?
What is Senores Pharmaceuticals IPO Issue Size?
What is Senores Pharmaceuticals IPO Price Band?
What is Senores Pharmaceuticals IPO Lot Size?
What is the Senores Pharmaceuticals IPO Allotment Date?
What is the Senores Pharmaceuticals IPO Listing Date?
Note: The Senores Pharmaceuticals IPO price band and date are officially announced. The (Senores Pharmaceuticals IPO grey market premium) will be added to the IPO GMP page as it will start).
